CXCL1 |
|
-
(1)
Promote proliferation of ovarian cancer; induce breast cancer cells migration/invasion; facilitate uterine cervix cancer malignant processes;
-
(2)
Promote gastric cancer cells angiogenesis;
-
(3)
Promote gastric cancer cells lymph node metastasis;
-
(4)
Promote breast cancer cells and gastric cancer cells’ migration/ invasion;
-
(5)
Promote melanocytes malignant transformation
|
[8,11,12,14,20,34,36,69,70] |
CXCL5 |
|
-
(1)
Promote proliferation and migration of non-small cell lung cancer cells;
-
(2)
Promote the migration/invasion and EMT of papillary thyroid carcinoma cells;
-
(3)
Promote growth and progression of prostate cancer
|
[33,35,71] |
CXCL8 |
PI3K/AKT and ERK/MAPK signaling pathways |
|
[17,32,60] |
CXCL1/3 |
TGF-β signaling pathway |
|
[31] |
CXCL1/5 |
CXCR2/STAT3 pathway |
|
[7] |
CXCL1/2/4 |
NF-κB pathway |
|
[27] |
CXCL1/2/8 |
NF-κB pathway |
|
[37] |
CXCL12 |
|
-
(1)
Promote angiogenesis in colon tumors;
-
(2)
Promote proliferation and survival of breast cancer cells;
-
(3)
Facilitate cancer growth and EMT;
-
(4)
Increase cell proliferation in pancreatic cancer;
-
(5)
Promote metastasis in colorectal cancer
|
[38,39,40,42,43,46] |
CXCL11/12 |
β-arrestin signaling |
|
[41] |
CXCL13 |
NF-κB pathway, PI3K/AKT pathway, ERK/MAPK pathway, STAT3 pathway |
|
[30,44,45,47] |